Can IL-2 boost immune cells in HIV patients who failed treatment?
NCT ID NCT00113282
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether adding Interleukin-2 (IL-2) to standard HIV drugs could increase CD4 immune cells in patients whose current treatment was failing and who had very low CD4 counts (≤200). Fifty-seven adults with HIV-1 took part. The main goal was to see if their CD4 count could rise above 200 after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Interleukin-2 (IL-2)
- What this could lead to
- If successful, adding IL-2 could help HIV patients with very low immune cells raise their counts and better fight infections.
- What could go wrong
- This is a small, early-phase trial with only 57 participants. IL-2 can cause side effects, and the benefit may not last or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker service des Maladies Infectieuses
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men
- A pharmacist's touch: could structured medication reviews boost HIV treatment success?
- A new Fast-Track HIV care model aims to Re-Engage those lost to care
- Can a smartphone app curb HIV risk in south Korea's young gay men?